Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Research Article

How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy

Author(s): Hankyung Jun*, Sang K. Cho, Elmar R. Aliyev, Soeren Mattke and Sze-Chuan Suen

Volume 17, Issue 9, 2020

Page: [819 - 822] Pages: 4

DOI: 10.2174/1567205017666201203121907

Price: $65

Abstract

Background: Recent trials suggest that disease-modifying therapy (DMT) for Alzheimer’s disease may become available soon. With the expected high price and a large patient pool, the budget impact will be substantial.

Objective: We explore combinations of effectiveness and price under which a DMT is cost-effective.

Methods: We used an open-source model to conduct two-way scenario analyses for both payer and societal perspectives, varying price, and treatment effect size simultaneously. The analysis generates costeffectiveness threshold prices over a potential range of DMT effectiveness in patients aged 65+ with mild cognitive impairment due to Alzheimer’s disease in the US.

Results: Under the willingness-to-pay a threshold of $150,000 per quality-adjusted life year and assuming 30% risk reduction relative to the standard of care, the maximum cost-effective price of a DMT per patient per year is ~$22,000 and ~$15,000 from societal and payer perspectives, respectively.

Conclusion: Joint variation of price and treatment effect size can help assess the cost-effectiveness of a potential Alzheimer’s disease treatment.

Keywords: Alzheimer's disease, dementia, mild cognitive impairment, cost-effectiveness analysis, pricing, drug development, disease-modifying therapy.

« Previous Next »
[1]
FDA Accepts . Biogen’s aducanumab biologics license application for Alzheimer’s disease with priority review Biogen Website 2020.https://investors.biogen.com/news-releases/news-release-details/fda-accepts-biogens-aducanumab-biologics-license-application
[2]
EISAI and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer’s Disease At Alzheimer’s Association International Conference (AAIC) 2018.https://www.eisai.com/news/2018/news201866.html
[3]
Aisen PS. Continuing progress in Alzheimer’s disease trials: Cause for optimism. J Prev Alzheimers Dis 2017; 4(4): 211-2.
[http://dx.doi.org/10.14283/jpad.2017.34] [PMID: 29181483]
[4]
Sterner RM, Takahashi PY, Yu Ballard AC. Active vaccines for Alzheimer disease treatment. J Am Med Dir Assoc 2016; 17(9): 862.e11-5.
[http://dx.doi.org/10.1016/j.jamda.2016.06.009] [PMID: 27461865]
[5]
Goldman DP, Fillit H, Neumann P. Accelerating Alzheimer’s disease drug innovations from the research pipeline to patients. Alzheimers Dement 2018; 14(6): 833-6.
[http://dx.doi.org/10.1016/j.jalz.2018.02.007] [PMID: 29680407]
[6]
Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y) 2019; 5: 272-93.
[http://dx.doi.org/10.1016/j.trci.2019.05.008] [PMID: 31334330]
[7]
Liu JL, Hlávka JP, Hillestad R, Mattke S. Assessing the preparedness of the US health care system infrastructure for an Alzheimer’s treatment St Monica, CA RAND Corp 2017.https://www.rand.org/pubs/research_reports/RR2272.html
[8]
Anderson R, Knapp M, Wittenberg R, Handels R, Schott JM. Economic modelling of disease-modifying therapies in Alzheimer’s disease Pers Soc Serv Res Unit, LSE Mar 2018.
[9]
Budd D, Burns LC, Guo Z, L’italien G, Lapuerta P. Impact of early intervention and disease modification in patients with predementia Alzheimer’s disease: A Markov model simulation. Clinicoecon Outcomes Res 2011; 3(1): 189-95.
[http://dx.doi.org/10.2147/CEOR.S22265] [PMID: 22046104]
[10]
Green C, Handels R, Gustavsson A, et al. Assessing cost-effectiveness of early intervention in Alzheimer’s disease: An open-source modeling framework. Alzheimers Dement 2019; 15(10): 1309-21.
[http://dx.doi.org/10.1016/j.jalz.2019.05.004] [PMID: 31402324]
[11]
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014; 371(9): 796-7.
[http://dx.doi.org/10.1056/NEJMp1405158] [PMID: 25162885]
[12]
Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer’s disease: A multinational sample of 1222 patients. Alzheimers Dement 2011; 7(3): 318-27.
[http://dx.doi.org/10.1016/j.jalz.2010.09.001] [PMID: 21575872]
[13]
Marešová P, Dolejs J, Mohelska H, Bryan LK. Cost of treatment and care for people with Alzheimer’s disease: A meta- analysis. Curr Alzheimer Res 2019; 16(14): 1245-53.
[http://dx.doi.org/10.2174/1567205017666200102144640] [PMID: 31894748]
[14]
Wimo A, Jönsson L, Bond J, Prince M, Winblad B. Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013; 9(1): 1-11.e3.
[http://dx.doi.org/10.1016/j.jalz.2012.11.006] [PMID: 23305821]
[15]
221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer’s Disease (EMERGE). Clinical Trials Website 2019.https://clinicaltrials.gov/ct2/show/NCT02484547
[16]
Neumann PJ, Kuntz KM, Leon J, et al. Health utilities in Alzheimer’s disease: A cross-sectional study of patients and caregivers. Med Care 1999; 37(1): 27-32.
[http://dx.doi.org/10.1097/00005650-199901000-00005] [PMID: 10413389]
[17]
Dunn A, Grosse SD, Zuvekas SH. Adjusting health expenditures for inflation: A Review of measures for health services research in the United States. Health Serv Res 2018; 53(1): 175-96.
[http://dx.doi.org/10.1111/1475-6773.12612] [PMID: 27873305]
[18]
Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. Cost-Effectiveness in health and medicine. 2nd ed. New York, NY: Oxford University Press 2017.
[19]
Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer’s disease: A systematic review of cost-effectiveness analyses. Drugs 2012; 72(6): 789-802.
[http://dx.doi.org/10.2165/11631830-000000000-00000] [PMID: 22480339]
[20]
Sköldunger A, Johnell K, Winblad B, Wimo A. Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer’s disease--a simulation study. Curr Alzheimer Res 2013; 10(2): 207-16.
[http://dx.doi.org/10.2174/1567205011310020011] [PMID: 23036018]
[21]
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321(13): 1286-94.
[http://dx.doi.org/10.1001/jama.2019.2000] [PMID: 30938796]

Rights & Permissions Print Cite
Article Metrics
37
© 2024 Bentham Science Publishers | Privacy Policy